Back to top
more

ANI Pharmaceuticals (ANIP)

(Delayed Data from NSDQ)

$59.20 USD

59.20
312,253

+0.25 (0.42%)

Updated Aug 14, 2024 04:00 PM ET

After-Market: $59.32 +0.12 (0.20%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 29% (72 out of 250)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Why Earnings Season Could Be Great for ANI Pharmaceuticals (ANIP)

ANI Pharmaceuticals (ANIP) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Acadia (ACAD) Q1 Earnings Surpass Estimates, Revenues Miss

Acadia's (ACAD) earnings in the first quarter of 2024 beat the Zacks Consensus Estimate, while revenues miss the same.

Esperion (ESPR) Q1 Earnings Beat, Stock Up on Strong Revenues

Esperion's (ESPR) first-quarter earnings and sales beat estimates on the back of better-than-expected collaboration revenues.

Intra-Cellular (ITCI) Q1 Earnings and Sales Beat Estimates

Intra-Cellular (ITCI) reports first-quarter 2024 results, wherein both earnings and revenues beat estimates, driven by strong Caplyta sales.

Pacira (PCRX) Q1 Earnings Miss, Exparel Sales Drive Revenues

Pacira (PCRX) reports first-quarter 2024 results, wherein earnings miss but revenues beat estimates, driven by Exparel sales.

Dr. Reddy's (RDY) Q4 Earnings Top, North America Sales Grow

Dr. Reddy's (RDY) posts better-than-expected fiscal fourth-quarter results on growth in global generics revenues in North America as well as Emerging Markets.

Guardant (GH) Gears Up for Q1 Earnings: Here's What to Expect

Investors' focus will likely be on revenues generated by Guardant Health (GH) from its precision oncology testing business.

Rocket's (RCKT) Q1 Loss Narrower Than Expected, Sales Nil

Rocket Pharmaceuticals' (RCKT) first-quarter earnings beat estimates. Devoid of marketed drugs, the company did not report any revenues during the quarter.

Perrigo (PRGO) Q1 Earnings Surpass, Sales Miss Estimates

Perrigo (PRGO) reports mixed first-quarter 2024 results. Management reiterates its financial outlook for 2024.

Apellis' (APLS) Q1 Earnings Match Estimates, Revenues Beat

Apellis (APLS) reports first-quarter 2024 results, wherein earnings match the Zacks Consensus Estimate and revenues beat the same, driven by strong sales of Syfovre.

Novavax (NVAX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Novavax (NVAX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Absci (ABSI) to Report Q1 Earnings: Here's What to Expect

The focus is likely to be on progress on its pipeline candidates when generative AI drug creation company Absci (ABSI) reports first-quarter results.

What Will Sitio Royalties' (STR) Q1 Earnings Unveil?

Sitio Royalties (STR) beat the Zacks Consensus Estimate for earnings in three of the last four quarters and missed in the other, resulting in an earnings surprise of 155.6%, on average.

CRISPR (CRSP) to Report Q1 Earnings: What's in the Cards?

On CRISPR Therapeutics' (CRSP) first-quarter 2024 earnings call, investors' focus is likely to be on the updates related to the first sales numbers of its newly approved gene therapy, Casgevy.

ANI Pharmaceuticals (ANIP) to Post Q1 Earnings: What's in Store?

ANI Pharmaceuticals' (ANIP) revenues in the first quarter of 2024 are likely to have been driven by increased sales of its lead product, Cortrophin Gel, as well as growth in its generics business.

Iovance (IOVA) Gears Up for Q1 Earnings: Here's What to Expect

Investors' focus will likely be on Iovance's (IOVA) progress with its ongoing commercial launch for a recently approved melanoma drug. An update is also expected on its early-stage pipeline.

Viatris (VTRS) to Report Q1 Earnings: Is a Beat in Store?

Viatris' (VTRS) Q1 results are likely to gain from momentum in its branded and incremental revenues from new product launches.

Ultragenyx (RARE) Q1 Loss Wider Than Expected, Revenues Rise Y/Y

Ultragenyx (RARE) reports dismal first-quarter 2024 results, missing both earnings and revenue estimates, despite the year-over-year increase of Crysvita and Dojolvi sales.

Agios (AGIO) Q1 Earnings Surpass, Sales Miss Estimates

Agios (AGIO) reports mixed earnings results for first-quarter 2024. Though sales miss the mark, revenues from its sole marketed drug, Pyrukynd, rise sequentially and on a yearly basis.

Puma Biotechnology's (PBYI) Q1 Earnings and Revenues Beat

Puma Biotechnology (PBYI) reports narrower-than-expected first-quarter 2024 loss. The company maintains its revenue guidance for 2024.

ANI Pharmaceuticals (ANIP) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release

ANI (ANIP) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Kymera (KYMR) Q1 Loss Narrower Than Expected, Pipeline in Focus

Kymera (KYMR) reports a narrower-than-expected loss in the first quarter. The company expects the current cash balance to provide a runway into the first half of 2027.

Blueprint (BPMC) Q1 Earnings and Revenues Beat, Stock Rises

Blueprint (BPMC) gains from better-than-expected first-quarter 2024 results, driven by robust Ayvakit sales growth. The company raises its revenue guidance for 2024.

Is Amarin (AMRN) Stock Outpacing Its Medical Peers This Year?

Here is how Amarin (AMRN) and ANI Pharmaceuticals (ANIP) have performed compared to their sector so far this year.

Bausch (BHC) Q1 Earnings and Revenues Miss, Shares Fall

Bausch's (BHC) first-quarter earnings and sales miss their respective estimates. Its shares fall in response to the results.